Sunshine Guojian Pharmaceutical (Shanghai) Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Sunshine Guojian Pharmaceutical (Shanghai) has been growing earnings at an average annual rate of 36.8%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 2.6% per year. Sunshine Guojian Pharmaceutical (Shanghai)'s return on equity is 7%, and it has net margins of 29.7%.
Anahtar bilgiler
36.8%
Kazanç büyüme oranı
33.5%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 11.3% |
Gelir büyüme oranı | 2.6% |
Özkaynak getirisi | 7.0% |
Net Marj | 29.7% |
Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 29We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings
Mar 31Recent updates
Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 29There's Reason For Concern Over Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) Massive 30% Price Jump
Oct 01What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You
Jul 25Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?
Jun 20If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity
May 24We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings
Mar 31Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04Gelir ve Gider Dağılımı
Sunshine Guojian Pharmaceutical (Shanghai) nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Sep 24 | 1,223 | 364 | 313 | 357 |
30 Jun 24 | 1,133 | 329 | 321 | 300 |
31 Mar 24 | 1,074 | 352 | 309 | 275 |
31 Dec 23 | 1,014 | 295 | 308 | 282 |
30 Sep 23 | 1,029 | 212 | 330 | 276 |
30 Jun 23 | 963 | 151 | 324 | 296 |
31 Mar 23 | 872 | 82 | 332 | 309 |
31 Dec 22 | 825 | 49 | 339 | 313 |
30 Sep 22 | 828 | 14 | 347 | 354 |
30 Jun 22 | 791 | -12 | 329 | 388 |
31 Mar 22 | 934 | 50 | 344 | 423 |
31 Dec 21 | 929 | 18 | 368 | 455 |
30 Sep 21 | 697 | -155 | 387 | 420 |
30 Jun 21 | 783 | -137 | 452 | 390 |
31 Mar 21 | 757 | -148 | 463 | 366 |
31 Dec 20 | 655 | -217 | 466 | 340 |
30 Sep 20 | 1,009 | 117 | 463 | 322 |
30 Jun 20 | 1,011 | 154 | 450 | 313 |
31 Mar 20 | 1,155 | 194 | 569 | 296 |
31 Dec 19 | 1,177 | 229 | 570 | 279 |
31 Dec 18 | 1,142 | 370 | 473 | 199 |
31 Dec 17 | 1,103 | 389 | 445 | 122 |
31 Dec 15 | 877 | 211 | 456 | 0 |
31 Dec 14 | 776 | 212 | 455 | 0 |
31 Dec 13 | 728 | 295 | 342 | 0 |
Kaliteli Kazançlar: 688336 has a large one-off gain of CN¥104.2M impacting its last 12 months of financial results to 30th September, 2024.
Büyüyen Kar Marjı: 688336's current net profit margins (29.7%) are higher than last year (20.6%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 688336's earnings have grown significantly by 36.8% per year over the past 5 years.
Büyüme Hızlandırma: 688336's earnings growth over the past year (71.5%) exceeds its 5-year average (36.8% per year).
Kazançlar vs. Sektör: 688336 earnings growth over the past year (71.5%) exceeded the Biotechs industry 0.08%.
Özkaynak Getirisi
Yüksek ROE: 688336's Return on Equity (7%) is considered low.